TW202400575A - 治療癌症的組合物和方法 - Google Patents

治療癌症的組合物和方法 Download PDF

Info

Publication number
TW202400575A
TW202400575A TW112110936A TW112110936A TW202400575A TW 202400575 A TW202400575 A TW 202400575A TW 112110936 A TW112110936 A TW 112110936A TW 112110936 A TW112110936 A TW 112110936A TW 202400575 A TW202400575 A TW 202400575A
Authority
TW
Taiwan
Prior art keywords
compound
ester
pharmaceutically acceptable
stereoisomer
hydrate
Prior art date
Application number
TW112110936A
Other languages
English (en)
Chinese (zh)
Inventor
林采旼
書立哈 凡帕堤
爾登 貝納盧
伯居 卡利司肯
奧茲葛 沙欣
Original Assignee
美商Ａ２Ａ製藥公司
美商腫瘤立方醫療有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商Ａ２Ａ製藥公司, 美商腫瘤立方醫療有限公司 filed Critical 美商Ａ２Ａ製藥公司
Publication of TW202400575A publication Critical patent/TW202400575A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW112110936A 2022-03-24 2023-03-23 治療癌症的組合物和方法 TW202400575A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263323339P 2022-03-24 2022-03-24
US63/323,339 2022-03-24

Publications (1)

Publication Number Publication Date
TW202400575A true TW202400575A (zh) 2024-01-01

Family

ID=88102078

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112110936A TW202400575A (zh) 2022-03-24 2023-03-23 治療癌症的組合物和方法

Country Status (10)

Country Link
US (2) US20250206728A1 (https=)
EP (1) EP4499625A4 (https=)
JP (1) JP2025509965A (https=)
KR (1) KR20250005157A (https=)
CN (2) CN119522217A (https=)
AU (1) AU2023241042A1 (https=)
CA (1) CA3246244A1 (https=)
IL (1) IL315800A (https=)
TW (1) TW202400575A (https=)
WO (1) WO2023183520A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4499625A4 (en) 2022-03-24 2026-03-18 A2A Pharmaceuticals Inc CANCER COMPOSITIONS AND TREATMENT METHODS
TW202530204A (zh) * 2023-09-27 2025-08-01 美商Ａ２Ａ製藥公司 用於治療與轉化酸性捲曲螺旋蛋白相關的癌症的方法
WO2026026956A1 (zh) * 2024-08-02 2026-02-05 北京康辰药业股份有限公司 Tacc抑制剂化合物、药物组合物及其制备方法和应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
EP1794135A1 (en) * 2004-09-27 2007-06-13 Amgen Inc. Substituted heterocyclic compounds and methods of use
US20080207572A1 (en) 2005-07-14 2008-08-28 Ab Science Use of Dual C-Kit/Fgfr3 Inhibitors for Treating Multiple Myeloma
EP2043651A2 (en) 2006-07-05 2009-04-08 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
US20130023534A1 (en) 2010-03-26 2013-01-24 Casillas Linda N Pyrazolyl-pyrimidines as kinase inhibitors
JP5947818B2 (ja) * 2011-03-02 2016-07-06 リード ディスカバリー センター ゲーエムベーハー 薬学的活性化二置換ピリジン誘導体
PE20142098A1 (es) * 2012-01-06 2015-01-08 Agios Pharmaceuticals Inc Compuestos terapeuticamente activos y sus metodos de uso
JP6008305B2 (ja) 2012-05-02 2016-10-19 公益財団法人がん研究会 Ｔａｃｃ３を標的とする小化合物
WO2015082583A1 (en) 2013-12-05 2015-06-11 F. Hoffmann-La Roche Ag Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality
US9796701B2 (en) 2013-12-31 2017-10-24 Xuanzhu Pharma Co., Ltd. Kinase inhibitor and use thereof
JP6682221B2 (ja) 2014-09-24 2020-04-15 公益財団法人がん研究会 Ｔａｃｃ３阻害剤のスクリーニング方法
EP3070084A1 (en) 2015-03-18 2016-09-21 Rottapharm Biotech S.r.l. New fyn kinase inhibitors
WO2016173557A1 (zh) 2015-04-30 2016-11-03 中国科学院上海药物研究所 一类具有激酶抑制活性的化合物、制备方法和用途
MX2017015574A (es) 2015-06-02 2018-08-09 Pharmacyclics Llc Inhibidores de tirosina quinasa de bruton.
TWI620748B (zh) 2016-02-05 2018-04-11 National Health Research Institutes 氨基噻唑化合物及其用途
ES2805976T3 (es) 2016-06-30 2021-02-16 Janssen Pharmaceutica Nv Derivados heteroaromáticos en calidad de inhibidores de NIK
WO2018045957A1 (zh) 2016-09-07 2018-03-15 江苏豪森药业集团有限公司 一种cdk4/6抑制剂及其制备方法和应用
WO2018124001A1 (ja) 2016-12-27 2018-07-05 国立研究開発法人理化学研究所 Ｂｍｐシグナル阻害化合物
CN107089968B (zh) 2017-04-12 2019-06-18 南方医科大学 1-(2-氨基吡啶-4-基)-3-哌啶甲酰胺衍生物及其合成方法和应用
TWI667236B (zh) 2017-06-13 2019-08-01 財團法人國家衛生研究院 作為蛋白激酶抑制劑的胺基噻唑化合物
MX2020004536A (es) 2017-11-23 2020-08-03 Biomed X Gmbh Derivados de pirimidina como inhibidores del receptor de tropomiosina quinasa (trka).
JP2021514359A (ja) 2018-02-15 2021-06-10 ニューベイション・バイオ・インコーポレイテッドＮｕｖａｔｉｏｎ Ｂｉｏ Ｉｎｃ． キナーゼ阻害剤としての複素環式化合物
WO2019177374A1 (ko) 2018-03-13 2019-09-19 포로노이바이오 주식회사 2, 4, 5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 또는 염증질환의 예방 또는 치료용 약학적 조성물
CN112469414A (zh) 2018-05-25 2021-03-09 昂科库博疗法有限责任公司 作为新型候选抗癌药物的高效力tacc3抑制剂
CN114502536A (zh) 2019-08-14 2022-05-13 诺维逊生物股份有限公司 作为激酶抑制剂的杂环化合物
CN115279754A (zh) * 2019-11-14 2022-11-01 A2A制药有限公司 靶向tacc3的异恶唑衍生物作为抗癌剂
KR20240005751A (ko) 2021-04-12 2024-01-12 에이2에이 파마수티칼스, 잉크. 암 치료를 위한 조성물 및 방법
EP4198097B1 (en) 2021-12-15 2024-05-29 Ricoh Company, Ltd. Image forming method and active energy ray-curable composition set
EP4499625A4 (en) 2022-03-24 2026-03-18 A2A Pharmaceuticals Inc CANCER COMPOSITIONS AND TREATMENT METHODS

Also Published As

Publication number Publication date
EP4499625A1 (en) 2025-02-05
JP2025509965A (ja) 2025-04-11
WO2023183520A1 (en) 2023-09-28
CN119522217A (zh) 2025-02-25
US20240156813A1 (en) 2024-05-16
AU2023241042A1 (en) 2024-10-10
EP4499625A4 (en) 2026-03-18
KR20250005157A (ko) 2025-01-09
CN120040441A (zh) 2025-05-27
US11986475B1 (en) 2024-05-21
US20250206728A1 (en) 2025-06-26
IL315800A (en) 2024-11-01
CA3246244A1 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
TW202400575A (zh) 治療癌症的組合物和方法
CN101687857B (zh) 嘧啶基哒嗪酮衍生物
JP2023154005A (ja) 血液疾患を処置するための化合物及び組成物
ES2906785T3 (es) Pirazoles 3,5-disustituidos útiles como inhibidores de la quinasa de punto de control 1 (CHK1), y sus preparaciones y aplicaciones
CN111201223A (zh) SHP2的八氢环戊二烯并[c]吡咯别构抑制剂
EP3880677A1 (en) Erk inhibitors and uses thereof
BR112017010354B1 (pt) Compostos de triazolopirimidina e usos dos mesmos
WO2012000304A1 (zh) 杂环炔苯类化合物及其药用组合物和应用
BR112015020772B1 (pt) Compostos de pirimidina e piridina e seu uso
EA019534B1 (ru) ПРОИЗВОДНЫЕ 3-(3-ПИРИМИДИН-2-ИЛБЕНЗИЛ)-1,2,4-ТРИАЗОЛО[4,3-b]ПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Met КИНАЗЫ
KR20240005751A (ko) 암 치료를 위한 조성물 및 방법
JP2023550739A (ja) 疾患及び障害を治療する方法
JP2025535816A (ja) 縮合複素環化合物及びその使用
WO2024137984A1 (en) Inhibitors of kif18a and uses thereof
WO2023109751A1 (zh) 嘧啶或吡啶类衍生物及其医药用途
JP2018536692A (ja) 新規なジヒドロピラノピリミジノン誘導体およびその用途｛Ｎｏｖｅｌ ｄｉｈｙｄｒｏｐｙｒａｎｏｐｙｒｉｍｉｄｉｎｏｎｅ ｄｅｒｉｖａｔｉｖｅｓ、ａｎｄ ｕｓｅ ｔｈｅｒｅｏｆ｝
CN119654323A (zh) 外核苷酸焦磷酸酶-磷酸二酯酶-1抑制剂和含其的医药组合物
CA3074885A1 (en) Aromatic derivative, preparation method for same, and medical applications thereof
WO2023207447A1 (zh) 吡咯并[2,3-d]嘧啶或吡唑并[3,4-d]嘧啶衍生物及其用途
TW202530204A (zh) 用於治療與轉化酸性捲曲螺旋蛋白相關的癌症的方法
WO2023078267A1 (zh) 作为蛋白激酶调节剂的含氨基大环化合物
CN110041302B (zh) 2-氨基-4-取代吡啶衍生物及其合成方法和应用
HK40121538A (zh) 用於治疗癌症的组合物和方法
HK40125804A (zh) 用於治疗癌症的组合物和方法
HK40103600A (zh) 用於治疗癌症的组合物和方法